It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EPRX’s FA Score shows that 0 FA rating(s) are green whileIRON’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EPRX’s TA Score shows that 5 TA indicator(s) are bullish while IRON’s TA Score has 4 bullish TA indicator(s).
EPRX (@Biotechnology) experienced а -4.78% price change this week, while IRON (@Biotechnology) price change was +28.67% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.
EPRX is expected to report earnings on Nov 05, 2025.
IRON is expected to report earnings on Nov 06, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
EPRX | IRON | EPRX / IRON | |
Capitalization | 292M | 3.13B | 9% |
EBITDA | -28.83M | -142.42M | 20% |
Gain YTD | 82.334 | 41.861 | 197% |
P/E Ratio | N/A | N/A | - |
Revenue | 0 | 0 | - |
Total Cash | 19.8M | 650M | 3% |
Total Debt | 35.1K | 30.9M | 0% |
EPRX | IRON | |
---|---|---|
RSI ODDS (%) | 2 days ago68% | 2 days ago74% |
Stochastic ODDS (%) | 2 days ago68% | 2 days ago82% |
Momentum ODDS (%) | 2 days ago66% | 2 days ago81% |
MACD ODDS (%) | 2 days ago61% | 2 days ago79% |
TrendWeek ODDS (%) | 2 days ago65% | 2 days ago84% |
TrendMonth ODDS (%) | 2 days ago43% | 2 days ago86% |
Advances ODDS (%) | 10 days ago81% | 4 days ago83% |
Declines ODDS (%) | 2 days ago72% | N/A |
BollingerBands ODDS (%) | 2 days ago78% | 2 days ago73% |
Aroon ODDS (%) | 2 days ago70% | 2 days ago90% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FNIAX | 48.29 | N/A | N/A |
Fidelity Advisor New Insights A | |||
FIKLX | 10.41 | N/A | N/A |
Fidelity Advisor Intl Real Estate Z | |||
FAKDX | 9.63 | N/A | N/A |
Kempner Multi-Cap Deep Value Investor | |||
GEMUX | 29.98 | -0.06 | -0.20% |
Goldman Sachs Emerging Markets Eq R6 | |||
SPYGX | 22.56 | -0.07 | -0.31% |
Spyglass Growth Institutional |
A.I.dvisor tells us that EPRX and NAGE have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EPRX and NAGE's prices will move in lockstep.
Ticker / NAME | Correlation To EPRX | 1D Price Change % | ||
---|---|---|---|---|
EPRX | 100% | -1.53% | ||
NAGE - EPRX | 33% Poorly correlated | -1.21% | ||
ETNB - EPRX | 29% Poorly correlated | -0.07% | ||
ACAD - EPRX | 28% Poorly correlated | +1.31% | ||
IRON - EPRX | 28% Poorly correlated | +20.95% | ||
IOVA - EPRX | 26% Poorly correlated | -2.68% | ||
More |
A.I.dvisor indicates that over the last year, IRON has been loosely correlated with NUVL. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IRON jumps, then NUVL could also see price increases.
Ticker / NAME | Correlation To IRON | 1D Price Change % | ||
---|---|---|---|---|
IRON | 100% | +20.95% | ||
NUVL - IRON | 54% Loosely correlated | +2.32% | ||
KMSTF - IRON | 54% Loosely correlated | N/A | ||
IDYA - IRON | 51% Loosely correlated | +5.67% | ||
SYRE - IRON | 51% Loosely correlated | +1.03% | ||
CGON - IRON | 51% Loosely correlated | -0.93% | ||
More |